Gamida Cell Ltd
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel. Show More...
-
Website https://www.gamida-cell.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.02 USD
-
Last Updated 26-04-2024
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -1.26 -1.06 -10.53 -1.69 -1.38 Dividends USD Payout Ratio % * Shares Mil 18.0 18.0 5.0 29.0 32.0 Book Value Per Share * USD 0.16 1.45 0.53 Free Cash Flow Per Share * USD -1.33 -1.12 Return on Assets % -118.21 -59.32 -96.16 -51.29 -49.92 Financial Leverage (Average) 1.75 1.96 2.64 1.96 2.25 Return on Equity % -207.29 -112.31 -222.38 -115.14 -153.26 Return on Invested Capital % -208.57 -114.08 -224.99 -97.2 -139.25 Interest Coverage -984.7 -632.7 -776.37 -42.57 10.77 Current Ratio 9.71 9.53 9.28 4.98 4.15 Quick Ratio 9.51 7.89 9.05 4.86 3.99 Debt/Equity 0.12 0.19